AAP
OCUL icon

Arax Advisory Partners’s Ocular Therapeutix OCUL Stock Holding History

Arax Advisory Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.4K Buy
3,709
+3,206
+637% +$29.1K ﹤0.01% 3527
2026
Q1 		$4.26K Buy
503
+125
+33% +$1.19K ﹤0.01% 2864
2025
Q4 		$4.59K Buy
+378
New +$4.59K ﹤0.01% 2901
2025
Q3 		– Sell
-87
Closed -$808 – 4080
2025
Q2 		$808 Hold
87
– – ﹤0.01% 2848
2025
Q1 		$638 Sell
87
-187
-68% -$1.44K ﹤0.01% 2480
2024
Q4 		$2.34K Hold
274
– – ﹤0.01% 1972
2024
Q3 		$2.38K Hold
274
– – ﹤0.01% 1998
2024
Q2 		$1.88K Buy
+274
New +$1.69K ﹤0.01% 1987

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Arax Advisory Partners's OCUL Position: Q2 2026 in Review

Arax Advisory Partners increased its Ocular Therapeutix (OCUL) stake by 637% in Q2 2026, buying an estimated $29.1K and bringing the position to 3,709 shares worth $36.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3527.

Arax Advisory Partners first reported a position in OCUL in Q2 2024 and has held it in 8 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Arax Advisory Partners held 3,709 shares of Ocular Therapeutix worth $36.4K as of Q2 2026.
  • Arax Advisory Partners bought 3,206 Ocular Therapeutix shares in Q2 2026, an estimated $29.1K.
  • Ocular Therapeutix made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3527 holding.
  • Arax Advisory Partners first reported a position in Ocular Therapeutix in Q2 2024 and has held it in 8 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.